ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids

ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids

Chemotherapy resistance is a major challenge in ovarian cancer (OvCa). Thus, novel treatment combinations are highly warranted. However, many promising drug candidates tested in two-dimensional (2D) cell culture have not proved successful in the clinic. For this reason, we analyzed our drug combinat...

Full description

Bibliographic Details
Main Authors: Nina Hedemann, Andreas Herz, Jan Hendrik Schiepanski, Jan Dittrich, Susanne Sebens, Astrid Dempfle, Julia Feuerborn, Christoph Rogmans, Nils Tribian, Inken Flörkemeier, Jörg Weimer, Sandra Krüger, Nicolai Maass, Dirk O. Bauerschlag
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
ovarian cancer
chemotherapy resistance
combined therapy
ADAM17
3D model
drug testing
Online Access:https://www.mdpi.com/2072-6694/13/9/2039

Internet

https://www.mdpi.com/2072-6694/13/9/2039

Similar Items